Biogen Reports TYSABRI Data Show Significant Reductions in MS Disease Activity
October 03, 2013 at 06:00 AM EDT
Biogen Idec (NASDAQ: BIIB ) today announced results from several new analyses of TYSABRI® (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis (MS) disease activity. This
